XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. The research was published earlier this month in the journal Cell.

DNA 98

DNA Gene Gene Silencing Genome 98

Drug Discovery World

SEPTEMBER 5, 2022

Knockout’ mice are bred in a laboratory with specific genes silenced or ‘knocked out’. They have been valuable tools for research on a wide range of diseases and conditions, used in 4,676 published papers so far. For example, the knockout mice have helped identify genes related to eye disease and autism spectrum disorder.

Gene Silencing 52

Gene Silencing Gene Genetics Genome 52

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. The research was published earlier this month in the journal Cell. pyogenes dCas9.

DNA 52

DNA Gene Gene Silencing Genome 52

Drug Discovery World

OCTOBER 4, 2022

As one of the exciting fields in the pharmaceutical industry, it’s no surprise that Drug Discovery 2022 will feature sessions on developments in CAR-T and the technologies helping researchers in this field. . Other sessions will explore the benefits of automation and give insight into how it can help researchers and labs gain value. .

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

AUGUST 1, 2023

As such, through collaboration with the biotechnology company Ionis Pharmaceuticals and the University of Gothenburg, AstraZeneca are developing an ASO that can target liver cells to ‘silence’ PNPLA3 with the aim of restoring fat break down in the liver. Though some genetic mutations are harmful, others can be protective.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.

Gene Editing 52

Gene Editing Gene Engineer DNA 52